Li-butol: anti-tuberculosis drug from India
Li-butol is an anti-tuberculosis drug manufactured in India by Laika Labs Ltd. This medicine belongs to the group of anti-tuberculosis drugs of different chemical groups and contains the active substance - ethambutol.
Li-butol is available in tablets of various strengths - 200 mg, 400 mg and 800 mg. This drug is used to treat tuberculosis, one of the most common infectious diseases in the world.
Like any medicine, Li-butol has its contraindications and limitations for use. It should not be used in cases of hypersensitivity to ethambutol, gout, optic neuritis, cataracts, inflammatory eye diseases, diabetic retinopathy, renal impairment and pregnancy. It is also necessary to stop breastfeeding during treatment.
When using Li-butol, side effects may occur, such as dyspeptic symptoms (nausea, vomiting, abdominal pain), dizziness, spatial disorientation, hallucinations, peripheral neuritis, optic neuritis, exacerbation of gout, leukopenia, hyperuricemia and allergic reactions.
It is important to remember that Li-butol can interact with other medications, increasing their effects and neurotoxicity. These drugs include aminoglycosides, asparaginase, carbamazepine, ciprofloxacin, imipenem, lithium salts, methotrexate and quinine.
There is no data on an overdose of Li-butol, but if symptoms of an overdose occur, you should seek medical help.
In general, Li-butol is an effective anti-tuberculosis agent, but its use should only be under medical supervision. If any side effects occur, seek medical attention immediately.